Cardiotonic Drugs from the Avicenna's Point of View.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. UHPLC-Q-TOF-MS/MS and Network Pharmacology Analysis to Reveal Quality Markers of XinjiangBioMed research international · 2022
   Article
2. A Randomized, Triple-Blind, Placebo-Controlled, Add-On Clinical Trial to Evaluate the Efficacy ofEvidence-based complementary and alternative medicine : eCAM · 2020
   Article
3. A systematic review on the cardiovascular pharmacology ofJournal of cardiovascular and thoracic research · 2018
   Review
4. Multitarget anticancer profiling of Withania somnifera - Dual herbal combination with P. emblica, B. monnieri, and O. basilicum through integrated In silico docking and In vitro Jurkat cell line analysis.Journal of Ayurveda and integrative medicine
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.